Dr.NahalRx

06/01/2026

🚨 Potential Breakthrough in Metastatic Pancreatic Cancer 🚨

One of the most exciting presentations at ASCO 2026 may change the treatment landscape for patients with advanced pancreatic cancer harboring a KRAS G12D mutation.

The phase 3 RASolute 302 trial evaluated daraxonrasib, a targeted KRAS G12D inhibitor, in patients with metastatic pancreatic cancer whose disease had progressed after standard chemotherapy.

📊 Key Results:
• Median Overall Survival (OS): 13.2 months vs. 6.6 months
• Nearly doubled overall survival!!
• Demonstrated the power of precision medicine in a disease that has historically had very limited treatment options

Why this matters:
Pancreatic cancer remains one of the most aggressive and difficult-to-treat cancers. For years, treatment options after first-line chemotherapy have offered only modest benefit. These results suggest that biomarker-driven therapy may finally be making a meaningful impact for a subset of patients.

This study also reinforces the importance of comprehensive molecular testing in pancreatic cancer to identify actionable mutations such as KRAS G12D.

While we await regulatory review and guideline updates, this could represent a major step forward in personalized treatment for pancreatic cancer.

TargetedTherapy KRAS CancerResearch OncTwitter HematologyOncology Pharmacy

05/29/2026

The FDA has approved durvalumab (Imfinzi) in combination with BCG for certain patients with high-risk non-muscle invasive bladder cancer.

As oncology professionals, we continue to see immunotherapy move earlier in the treatment journey, offering new options for patients who historically had limited alternatives beyond intravesical therapy and surgery.

Every new approval represents years of research, clinical trial participation, and hope for patients and families facing cancer.

Excited to see how this impacts treatment pathways and patient outcomes in the real world.

FDAApproval ValueBasedCare

05/29/2026

Cancer treatments, but make it astrology. ♈♉♊

From bold CAR-T therapy as Aries to detail-obsessed precision medicine as Virgo, each zodiac sign gets matched with a cancer treatment personality.

This carousel is a fun, lighthearted way to explain oncology concepts while showing how different treatments each play a unique role in cancer care.

Which cancer treatment matches your sign?

05/25/2026

“Grade Group 1” sounds harmless… until you realize how much language shapes patient behavior.

A new report in JAMA Oncology suggests that relabeling low-grade prostate cancer as “precancerous” could actually reduce prostate cancer mortality overall by increasing screening uptake and reducing fear around diagnosis.

This is one of the most important concepts in oncology that people outside the field rarely think about:

Words change decisions.
Decisions change outcomes.

We’ve seen patients panic at the word “cancer,” while others avoid screening entirely because they fear the diagnosis more than the disease itself. Meanwhile, many Grade Group 1 prostate cancers are managed with active surveillance, not immediate aggressive treatment.

The challenge is balance:
• Avoid overtreatment
• Avoid undertesting
• Avoid minimizing risk
• Still communicate honestly

This is where precision medicine and value-based oncology intersect with psychology and public health.

Sometimes the hardest part of cancer care isn’t the science.
It’s explaining risk in a way patients can actually process.

OncologyPharmacy HealthcareLeadership JAMAOncology

05/21/2026

Oncology pharmacy, but make it fashionably evidence-based ☀️🧴

Summer reminder: skin cancer is one of the most common cancers, yet so many people still underestimate sun protection.

As an oncology pharmacist, I spend my days reviewing treatments for cancers that many people think could “never happen to them.” Immunotherapy, targeted therapy, toxicities, biomarkers, prior auths, dosing adjustments… all for diseases that sometimes started with years of unprotected sun exposure.

Wear the sunscreen.
Reapply it.
Get the skin check.
And yes, tanning damage adds up over time.

Prevention will always be one of the most powerful treatments we have. ✨

05/16/2026

11 years ago, I graduated pharmacy school with no perfect roadmap.

My path was not linear: compounding, long-term care, specialty pharmacy, oncology clinical review, management, and now Director of Care Management.

What I would do differently:
I would compare myself less, network earlier, trust myself sooner, and learn the business side of healthcare earlier.

What I would not change:
Taking unconventional roles, saying yes before I felt ready, and building real expertise through experience.

11 years later, I’ve learned that your career does not have to look like anyone else’s to be successful.

Keep building. The path makes more sense later.

05/15/2026

05/09/2026

Not every woman needs a breast MRI, but for high-risk patients, it can be an important screening tool used alongside mammography. Talk to your healthcare provider about what screening plan is right for you 🩷

05/09/2026

Alternating MRI and mammography every 6 months isn’t “doing extra.” It’s using different screening modalities to catch what another might miss. 🎗️

A mammogram and a breast MRI don’t look at the breast tissue the same way. Some cancers are more visible on MRI, while mammography can pick up calcifications that MRI may not.

That’s why many high-risk screening protocols alternate them:

▫️ Mammogram
▫️ 6 months later: MRI
▫️ 6 months later: Mammogram again

The goal is more consistent surveillance throughout the year, especially for patients with dense breast tissue, genetic risk factors, or strong family history.

Early detection isn’t one-size-fits-all. Different modalities provide different information and together they create a more complete picture. 💕

OncologyPharmacist WomenInHealthcare BreastHea